West Pharmaceutical Services, Inc. (NYSE:WST) – Jefferies Group raised their FY2017 earnings estimates for West Pharmaceutical Services in a research note issued on Thursday. Jefferies Group analyst D. Windley now anticipates that the medical instruments supplier will post earnings per share of $2.77 for the year, up from their prior forecast of $2.67. Jefferies Group has a “Buy” rating and a $115.00 price target on the stock. Jefferies Group also issued estimates for West Pharmaceutical Services’ Q4 2017 earnings at $0.62 EPS, Q1 2018 earnings at $0.82 EPS, Q3 2018 earnings at $0.68 EPS and Q4 2018 earnings at $0.70 EPS.

Several other brokerages have also recently issued reports on WST. Stephens initiated coverage on West Pharmaceutical Services in a research note on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price objective on the stock. BidaskClub cut West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Zacks Investment Research cut West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Bank of America Corporation cut West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective on the stock. in a research note on Tuesday, October 17th. Finally, Wells Fargo & Company increased their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $106.00.

ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/30/fy2017-eps-estimates-for-west-pharmaceutical-services-inc-wst-lifted-by-jefferies-group.html.

West Pharmaceutical Services (WST) opened at 101.16 on Monday. The stock has a market capitalization of $7.49 billion, a P/E ratio of 43.42 and a beta of 1.12. West Pharmaceutical Services has a one year low of $72.34 and a one year high of $103.36. The stock has a 50 day moving average price of $94.50 and a 200-day moving average price of $92.20.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.14. The business had revenue of $398.20 million during the quarter, compared to analyst estimates of $386.02 million. West Pharmaceutical Services had a return on equity of 14.90% and a net margin of 12.12%. West Pharmaceutical Services’s revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 EPS.

Large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its holdings in West Pharmaceutical Services by 2.3% in the second quarter. The Manufacturers Life Insurance Company now owns 108,158 shares of the medical instruments supplier’s stock valued at $10,223,000 after buying an additional 2,427 shares during the last quarter. American Century Companies Inc. increased its holdings in West Pharmaceutical Services by 0.4% in the second quarter. American Century Companies Inc. now owns 701,364 shares of the medical instruments supplier’s stock valued at $66,293,000 after buying an additional 2,605 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in West Pharmaceutical Services by 16.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 88,252 shares of the medical instruments supplier’s stock valued at $8,342,000 after buying an additional 12,609 shares during the last quarter. CIBC Asset Management Inc purchased a new position in West Pharmaceutical Services in the second quarter valued at $223,000. Finally, Chatham Capital Group Inc. increased its holdings in West Pharmaceutical Services by 7.8% in the second quarter. Chatham Capital Group Inc. now owns 17,300 shares of the medical instruments supplier’s stock valued at $1,635,000 after buying an additional 1,245 shares during the last quarter. 90.17% of the stock is currently owned by hedge funds and other institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.